MarketWatch
Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes
The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.
View original source — MarketWatch ↗
Related stories
MarketWatch
BusinessJul 31, 2026 · 1 min
A spot is opening up in the S&P 500, and these stocks are top candidates to fill the void
MarketWatch
TASS
BusinessJul 31, 2026 · 1 min
Armenia’s exit would not lead to collapse of EAEU — expert
TASS
TASS
BusinessJul 31, 2026 · 1 min
Georgia’s GDP grows 7.9% year over year in 1H 2026
TASS
Lovin Malta
BusinessJul 31, 2026 · 1 min
Electrogas Documents and Schembri-Theuma Selfie Seized From Fenech’s Boardroom
Lovin Malta